This paper introduces a new-generation NK cell CEA-CAR therapy designed for the targeted treatment of CEA-expressing colorectal cancer (CRC) and presents its efficacy against multiple in vitro models of colon carcinoma. This evidence concerns the gene CEACAM5 and colorectal cancer.